3-(8-cyclohexyloctyl)-4-hydroxynaphthalene-1,2-dione | 14561-42-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 3-(8-cyclohexyloctyl)-4-hydroxynaphthalene-1,2-dione
• 英文别名: 2-hydroxy-3-(8-cyclohexyloctyl)-1,4-naphthoquinone；2-(8-cyclohexyloctyl)-3-hydroxynaphthalene-1,4-dione；menoctone；2-(8-cyclohexyloctyl)-3-hydroxy-1,4-naphthoquinone；2-Hydroxy-3-(ω-cyclohexyloctyl)-1,4-naphthoquinone；2-(8-Cyclohexyloctyl)-2-hydroxy-1,4-naphthochinon；2-Hydroxy-3-(8-cyclohexyloctyl)-1,4-naphthochinon
• CAS: 14561-42-3
• 化学式: C₂₄H₃₂O₃
• 分子量: 368.516
• InChiKey: MGDIRAXSDLCQGC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.58
• 重原子数：
  27.0
• 可旋转键数：
  9.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  54.37
• 氢给体数：
  1.0
• 氢受体数：
  3.0

安全信息

• 海关编码：
  2914690090

反应信息

• 作为产物：
  描述：

  5-苯基戊酸 在 铂 lithium aluminium tetrahydride 、 硫酸 、 氢溴酸 、 氢气 作用下， 生成 3-(8-cyclohexyloctyl)-4-hydroxynaphthalene-1,2-dione
  参考文献：
  名称：

  萘醌抗疟药。二十九。2-羟基-3-（ω-环己基烷基）-1,4-萘醌。

  摘要：

  DOI：

  10.1021/jm00316a001

文献信息

• Medicaments for the treatment of toxoplasmosis
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0567162A1

  公开（公告）日：1993-10-27

  The present invention relates to the use of 2-[4-(4-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone or a physiologically acceptable salt or other physiologically funtional derivative thereof for the manufacture of a medicament for the treatment and/or prophylaxis of toxoplasmosis in animals, to pharmaceutical compositions for the treatment and/or prophylaxis of toxoplasmosis, comprising said compound as active ingredient and to a method of treating or preventing toxoplasmosis in an animal which comprises administering to said animal an effective amount of said compound.

  本发明涉及2-[4-(4-氯苯基)环己基]-3-羟基-1,4-萘醌或其生理可接受的盐或其他生理功能衍生物用于制造治疗和/或预防动物弓形虫病的药物，涉及包含该化合物作为活性成分的治疗和/或预防弓形虫病的药物组合物，以及涉及治疗或预防动物弓形虫病的方法，该方法包括向所述动物施用有效量的该化合物。
• [EN] CARBONATE PRODRUGS AND METHODS OF USING THE SAME<br/>[FR] PROMÉDICAMENTS CARBONATÉS ET LEURS MÉTHODES D'UTILISATION
  申请人：NEUROGESX INC

  公开号：WO2009143297A1

  公开（公告）日：2009-11-26

  The present invention provides carbonate prodrugs which comprise a carbonic phosphoric anhydride prodrug moiety attached to the hydroxyl or carboxyl group of a parent drug moiety. The prodrugs may provide improved physicochemical properties over the parent drug. Also provided are methods of treating a disease or condition that is responsive to the parent drug using the carbonate prodrugs, as well as kits and unit dosages.

  本发明提供了碳酸盐前药，其包括连接到母药基团的羟基或羧基上的碳酸磷酸酐前药基团。这些前药可能比母药具有改进的物理化学性质。还提供了使用碳酸盐前药治疗对母药具有响应的疾病或症状的方法，以及配套工具和单剂量。
• [EN] PRODRUG COMPOSITIONS AND METHODS OF TREATMENT<br/>[FR] COMPOSITIONS DE PROMÉDICAMENT ET PROCÉDÉS DE TRAITEMENT
  申请人：AQUESTIVE THERAPEUTICS INC

  公开号：WO2021087359A1

  公开（公告）日：2021-05-06

  Pharmaceutical compositions include a prodrug of epinephrine are described.

  药物组合物包括表述的肾上腺素前药。
• Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
  申请人：Rogers D. Robin

  公开号：US20070093462A1

  公开（公告）日：2007-04-26

  Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.

  揭示了离子液体及制备活性药物、生物、营养和能量成分的离子液体组合物的方法。还揭示了利用本文描述的组合物的方法，以克服多型性、克服溶解度和输送问题、控制释放速率、增加功能性、增强功效（协同作用）以及改善易用性和制造工艺。
• [EN] DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF<br/>[FR] LIQUIDES IONIQUES À DOUBLE FONCTION ET SELS DE CEUX-CI
  申请人：UNIV ALABAMA

  公开号：WO2010078300A1

  公开（公告）日：2010-07-08

  Disclosed herein are ionic liquid compositions comprising active pharmaceutical, biological, and nutritional compounds, and methods of use. Further disclosed are compositions of matter including liquid ion pairs alone or in solution and their use; compositions of ionic liquids that are 'solvated,' for example, 'hydrated' and their uses.

  本文揭示了包括活性药物、生物学和营养化合物的离子液体组合物，以及其使用方法。进一步揭示了包括液态离子对的物质组合物，单独或溶解后使用；以及离子液体的“溶剂化”组合物，例如“水合”的组合物及其用途。